|View printer-friendly version|
|September 13, 2004 5:16 p.m.|
|Teva Enters Into Agreement With Schwarz Pharma to Suspend Sales of Moexipril Pending Outcome of Litigation|
Jerusalem, Israel, September 13, 2004 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that further to its press release dated January 31, 2004, the Company has entered into an agreement with Schwarz Pharma regarding Moexipril HCl Tablets, the AB-rated generic equivalents of Schwarz's antihypertensive agent Univasc® Tablets. Under the terms of the agreement, Teva will suspend all manufacturing and selling of its Moexipril HCl Tablets pending the outcome of litigation between the two companies in the U.S. District Court for the District of New Jersey or an Order of the Court.